Trial Supports Wider Use of Adalimumab in Uveitis

A UK clinical trial has shown that adalimumab protects sight in a far wider group of patients with non-infectious uveitis than previously recognised.
Findings published in eClinicalMedicine suggest eligibility criteria should be widened.
Uveitis is the inflammation of the uvea, which is the middle, pigmented layer of the eye containing the iris, ciliary body, and choroid. Non-infectious uveitis is a leading cause of blindness in high-income countries. Adalimumab is already used in the NHS for arthritis and some forms of ocular inflammation and is the only non-steroid treatment licensed in the UK for uveitis.
The ASTUTE trial, co-led by Oxford University Hospitals and Bristol NHS Foundation Trust, recruited patients at 18 UK hospitals. All received adalimumab for 16 weeks plus standard care. Responders were then randomised to continue the drug or placebo (double-blind).
At one year, 31.4% of those continuing adalimumab experienced relapse or needed further treatment, versus 59% on placebo. NICE guidance (2017) funds the drug only for a narrow set of patients; ~85% of those randomised in ASTUTE would not have met the criteria. In this “excluded” group, continued treatment reduced treatment-failure risk by 63%, with the same overall benefit.
Dr Srilakshmi Sharma, Consultant Medical Ophthalmologist at the Oxford Eye Hospital and co-chief investigator, said: “We set out to answer a question that patients have been asking us in clinic for years, which is whether this drug would help them if only they were allowed to have it. The answer is yes, for many of them. These are people who come to our clinics with their sight at risk, and who we currently have to tell that the funding rules do not cover them. We now have UK trial evidence, from NHS clinics and patients, that the rules are drawn in the wrong place.”
Side-effects were no more common with adalimumab than placebo. University of Oxford health economists estimated an extra annual cost of £662 per patient and £2320 per treatment failure avoided; a cheaper biosimilar was used.
Co-chief investigator Dr Andrew Dick (University of Bristol and UCL) said: “This trial was designed to be difficult to argue with. We treated everyone first, so we knew who responded, and only then did we randomise. That design let us show, cleanly, that stopping the drug in people who are doing well on it leads to relapse in most of them. The implication for practice is straightforward: when it works, it needs to be continued, and in many more patients than are currently eligible.”
Patients helped design the trial. It was supported by the Birdshot Uveitis Society and the NIHR Health Technology Assessment Programme and NIHR Biomedical Research Centres at Moorfields and Oxford. Annie Folkard (Birdshot Uveitis Society) noted that more than a hundred participants contributed over years and deserve an answer that could change access. The team has submitted the eligibility findings to NICE.
Source: Oxford University Health Service










